SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC) Meeting Abstract

  

Authors:	Rathkopf, D.; Dallos, M.; Stein, M.; Spina, C. S.; Deutsch, I.; Nguyen, C.; Okada, A.; Lloyd, M.; Manarite, J.; McBride, S.
Abstract Title:	SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Meeting Title:	ESMO Congress 2024
Journal Title:	Annals of Oncology
Volume:	35
Issue:	Suppl. 2
Meeting Dates:	2024 Sep 13-17
Meeting Location:	Barcelona, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2024-09-01
Start Page:	S995
End Page:	S996
Language:	English
ACCESSION:	WOS:001326612902274
DOI:	10.1016/j.annonc.2024.08.1733
PROVIDER:	wos
Notes:	Meeting Abstract: 1652P -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/224360